Yojee Limited

Quarterly Activity Update (30 June 2018): Yojee Limited (ASX: YOJ) released its Quarterly activity for the quarter ended 30 June 2018 wherein the group had total cash of $2.039 Mn and delivered multiple releases of its new 2.0 software which became live with customers from the middle of the quarter and we expect that it will provide new sales opportunities for the group in the upcoming period. During the quarter, the company entered into two foundational agreements with global logistics and supply chain leaders i.e., DB Schenker and UPS. Both agreements will help to increase the topline growth of the company in the forthcoming period at the back of identifying further opportunity in Asia market and Australia via collaborations and increasing technology network in the logistics sector. However, the company continues to expand its partnerships in the Asia Pacific region, the world’s largest logistics market with the objective of increasing its market share around the world. Based on aforesaid facts, the annual run-rate has improved across the quarter against the prior corresponding period (pcp) with software clients of about 25 in June 2018 from 4 in June 2017; and Yojee software of about A$129,866 in Q4FY18 from A$26,000 in Q4FY17.


Annual Run Rate (Source: Company Reports)

In the meantime, Thorney Technologies Ltd and its entities became the substantial holder of the group by holding 5.90 per cent voting rights. Besides this, TIGA Trading Pty Ltd and its entities also became the substantial holder of the group by holding 5.90 per cent voting rights since July 23, 2018. Meanwhile, the share price has fallen 22.22 per cent in the past three months as at August 15, 2018 and trading close to 52-week low level. Hence, we give a “Hold” recommendation on the stock at the current price of $0.105 (down 6.67% on August 16, 2018), considering foregoing updates and focus on to improving market share with the help of new agreements around the world.
 

Botanix Pharmaceuticals Limited

Growth Catalysts: Botanix Pharmaceuticals Limited (ASX: BOT) is a small-cap company with the market capitalization of $73.47 Mn as of August 16, 2018. During the period, the company has completed its first acne patient studies with BTX 1503 in January 2018 and started a Phase 2 clinical trial in June 2018 and this is expected to get completed by mid of 2019. Moreover, the phase 1b BTX 1204 atopic dermatitis patient study was successfully completed in June 2018 and currently focuses on progressing BTX 1204 into Phase 2 clinical development. For that matter, the group planned BTX 1204 Phase 2 clinical trial that will be a 10 to 12 week randomized, double-blind, vehicle-controlled study that includes patients with moderate AD therapies. This study will involve both US and Australian clinical sites and is expected to complete by mid-2019. Further, Phase 1b BTX 1308 psoriasis patient study is also scheduled to commence late Q3 CY18 and is expected to take approximately 6 months to complete. As of now, the company is pursuing a rapid clinical development strategy to accelerate product commercialization and timing to first generate revenues. As at June 30, 2018, the group had a cash reserve of $17.236 Mn and estimated cash outflow of $4.33 Mn for the next quarter.


Key Catalysts (Source: Company Reports)

Meanwhile, the stock tumbled 28.15 per cent in the past three months as at August 15, 2018 and is trading over 52-week low level. We give a “Hold” recommendation on the stock at the current price of $0.097 by looking at its strategy towards the commercialization of its product mix portfolio.

 
Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.